(Q37031891)

17 August 2017

1 reference

title

Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis (English)

1 reference

Mycobacterium tuberculosis

17 August 2017

0 references

0 references

2

Eric J Rubin

1 reference

17 August 2017

James C Sacchettini

1

1 reference

17 August 2017

Joel S Freundlich

series ordinal

3

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 January 2008

1 reference

Nature Reviews Microbiology

17 August 2017

number of pages

12

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

17 August 2017

volume

6

1 reference

17 August 2017

issue

1

1 reference

17 August 2017

page(s)

41-52

1 reference

High throughput crystallography of TB drug targets.

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

The common aromatic amino acid biosynthesis pathway is essential in Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Synthesis and biological activity of 3'-hydroxy-5'-aminobenzoxazinorifamycin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Mechanism of action of antimycobacterial activity of the new benzoxazinorifamycin KRM-1648

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Streptomycin, a Substance Exhibiting Antibiotic Activity Against Gram-Positive and Gram-Negative Bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Tuberculosis - metabolism and respiration in the absence of growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Who puts the tubercle in tuberculosis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Tuberculosis: a problem with persistence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Antituberculosis drugs: ten years of research

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Challenges in tuberculosis drug research and development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Current strategies for identifying and validating targets for new treatment-shortening drugs for TB.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Structure-based maximal affinity model predicts small-molecule druggability.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Comprehensive identification of conditionally essential genes in mycobacteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: application to Mycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Controlling gene expression in mycobacteria with anhydrotetracycline and Tet repressor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Use of a tetracycline-inducible system for conditional expression in Mycobacterium tuberculosis and Mycobacterium smegmatis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Tetracycline-inducible gene regulation in mycobacteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Proteome-wide profiling of isoniazid targets in Mycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Navigating chemical space for biology and medicine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Innovative lead discovery strategies for tropical diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Integration of computational analysis as a sentinel tool in toxicological assessments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Characterization of the Mycobacterium tuberculosis iniBAC promoter, a promoter that responds to cell wall biosynthesis inhibition.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Crystal structure of the Mycobacterium tuberculosis enoyl-ACP reductase, InhA, in complex with NAD+ and a C16 fatty acyl substrate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Structure of isocitrate lyase, a persistence factor of Mycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

A novel inhibitor of Mycobacterium tuberculosis pantothenate synthetase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Identification of new diamine scaffolds with activity against Mycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Integration of virtual and high-throughput screening

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Virtual screening of chemical libraries

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Lead discovery using molecular docking

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Ligand-based virtual screening, parallel solution-phase and microwave-assisted synthesis as tools to identify and synthesize new inhibitors of mycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Search of chemical scaffolds for novel antituberculosis agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Ligand based virtual screening and biological evaluation of inhibitors of chorismate mutase (Rv1885c) from Mycobacterium tuberculosis H37Rv

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Design, synthesis, and evaluation of aza inhibitors of chorismate mutase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Structure-based inhibitor design of AccD5, an essential acyl-CoA carboxylase carboxyltransferase domain of Mycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Drugs for bad bugs: confronting the challenges of antibacterial discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Modification of the NADH of the Isoniazid Target (InhA) from Mycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Mechanism of thioamide drug action against tuberculosis and leprosy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

High Affinity InhA Inhibitors with Activity against Drug-Resistant Strains ofMycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Treatment failure in a case of extensively drug-resistant tuberculosis associated with selection of a GyrB mutant causing fluoroquinolone resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Gatifloxacin in combination with rifampicin in a murine tuberculosis model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

New tuberculosis therapeutics: a growing pipeline

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Antibacterial activity of DL 473, a new semisynthetic rifamycin derivative

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Effect of a new rifamycin derivative, rifalazil, on liver microsomal enzyme induction in rat and dog

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

ANTITUBERCULOUS AGENTS. II. N,N'-DIISOPROPYLETHYLENEDIAMINE AND ANALOGS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Diarylquinolines target subunit c of mycobacterial ATP synthase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Mechanism of antimicrobial action of metronidazole

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Nonreplicating persistence of mycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Metronidazole therapy in mice infected with tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Cross-linking in the Living Cell Locates the Site of Action of Oxazolidinone Antibiotics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Linezolid for the treatment of multidrug-resistant tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)--a report of ten cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Activity of RBx 7644 and RBx 8700, new investigational oxazolidinones, against Mycobacterium tuberculosis infected murine macrophages

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Genetic analysis of the beta-lactamases of Mycobacterium tuberculosis and Mycobacterium smegmatis and susceptibility to beta-lactam antibiotics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Characterization of novel Mycobacterium tuberculosis and Mycobacterium smegmatis mutants hypersusceptible to beta-lactam antibiotics.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Imipenem for treatment of tuberculosis in mice and humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Two decades of imipenem therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Activity of amoxicillin/clavulanate in patients with tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Crystal structure of the Mycobacterium fortuitum class A beta-lactamase: structural basis for broad substrate specificity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

History of the discovery and clinical introduction of chlorpromazine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

In-vitro and intracellular antimycobacterial activity of trifluoperazine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Chlorpromazine: A Drug Potentially Useful for Treating Mycobacterial Infections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Synthesis and antitubercular activity of quaternized promazine and promethazine derivatives

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Synthesis and antitubercular activity of phenothiazines with reduced binding to dopamine and serotonin receptors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

UCSF Chimera--a visualization system for exploratory research and analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Application of fluoroquinolone pharmacodynamics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Pharmacokinetic interactions of ceftazidime, imipenem and aztreonam with amikacin in healthy volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

Cloning and expression of Mycobacterium tuberculosis and Mycobacterium leprae dihydropteroate synthase in Escherichia coli

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

inferred from DOI database lookup

7 January 2021

based on heuristic

Nitroheterocyclic drugs with broad spectrum activity

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1816

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRMICRO1816

1 reference

Dimensions Publication ID

17 August 2017

1044143694

0 references

1 reference